Recursion Pharmaceuticals and Schrodinger leverage their respective AI drug discovery platforms to potentially develop distinguished therapeutic candidates.

Clinical trials, traditionally plagued by low success rates and high operational costs, are being reengineered through AI ...

Latest developments expand Predictive’s AI-driven drug discovery platform to include biomarker discovery and drug repurposing ...

indicating significant advancements in their drug discovery capabilities. The company’s proprietary AI-driven platform, PEDAL, demonstrates a high accuracy rate of 92% in predicting tumor ...

GBAC “Quantum Healthcare 2025” board blueprint—$3.2 B QC drug-discovery market, 42 % CAGR, 50–70 % faster R&D cycles ...

Predictive Oncology Inc. has updated shareholders on its advancements in AI-driven drug discovery, specifically in biomarker discovery and drug repurposing, amid a growing biomarker discovery ...

Artificial intelligence and robotics are revolutionizing drug discovery by automating laboratory processes and enabling rapid ...

Viva Biotech launches AI-driven drug discovery platform, transforming new drug R&D logic, enabling one-stop innovative drug discovery: Shanghai, China Friday, May 16, 2025, 12:00 ...

SINGAPORE] Imagine a world where life-saving treatments are discovered not in decades, but in just a few years. Nanyang ...

New York-based Pathos AI, a biotech company applying artificial intelligence (AI) to drug development, has announced a $365 ...